FDA Advisory Panel Backs TRUQAP® (Capivasertib) for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

FDA Advisory Committee Backs TRUQAP® (capivasertib) for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee has delivered a largely favorable assessment of TRUQAP,…

Read MoreFDA Advisory Panel Backs TRUQAP® (Capivasertib) for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

Contineum Therapeutics Announces Encouraging Topline Results from Exploratory Phase 1b Study of PIPE-791 in Chronic Pain

Contineum Therapeutics Announces Encouraging Topline Results from Exploratory Phase 1b Study of PIPE-791 in Chronic Pain Contineum Therapeutics, Inc. (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on advancing differentiated therapies…

Read MoreContineum Therapeutics Announces Encouraging Topline Results from Exploratory Phase 1b Study of PIPE-791 in Chronic Pain

Corcept’s Phase 2 Trial of Dazucorilant Shows Two-Year Survival Advantage in Amyotrophic Lateral Sclerosis Patients

Corcept’s Phase 2 Trial of Dazucorilant Shows Sustained Two-Year Survival Advantage in ALS Patients Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage biopharmaceutical company focused on developing therapies that modulate cortisol…

Read MoreCorcept’s Phase 2 Trial of Dazucorilant Shows Two-Year Survival Advantage in Amyotrophic Lateral Sclerosis Patients

Curocell’s RIMQARTO Injection Secures Full Regulatory Approval, Set to Enter CAR-T Market with 67% Complete Response Rate

Curocell’s RIMQARTO Injection Secures Full Regulatory Approval, Positioned to Enter CAR-T Market with 67% Complete Response Rate South Korean biotechnology company Curocell (KOSDAQ: 372320) has achieved a landmark milestone in…

Read MoreCurocell’s RIMQARTO Injection Secures Full Regulatory Approval, Set to Enter CAR-T Market with 67% Complete Response Rate

TRexBio Initiates Phase 1b Study of TRB-061 with First Patient Dosed in Moderate-to-Severe Atopic Dermatitis

TRexBio Initiates Phase 1b Study of TRB-061 in Moderate-to-Severe Atopic Dermatitis with First Patient Dosed TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company focused on discovering and developing immunoregulatory therapies…

Read MoreTRexBio Initiates Phase 1b Study of TRB-061 with First Patient Dosed in Moderate-to-Severe Atopic Dermatitis

ClearNote Health to Showcase Advanced Early Detection Results for Avantect® Pancreatic Cancer Test at Digestive Disease Week 2026

ClearNote Health to Showcase Leading Early Detection Results for Avantect® Pancreatic Cancer Test at Digestive Disease Week 2026 ClearNote Health, a biotechnology company focused on advancing early cancer detection, has…

Read MoreClearNote Health to Showcase Advanced Early Detection Results for Avantect® Pancreatic Cancer Test at Digestive Disease Week 2026